Your search for bevacizumab returned 123 results

Study shows reductions in intraocular pressures and antiglaucoma medication use.

The FDA has approved Keytruda (pembrolizumab; Merck), a programmed death receptor-1 -blocking antibody, as monotherapy for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer

Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.

And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.

Pfizer announced the launch of 3 new biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab-qyyp).  Zirabev, a biosimilar to Avastin (bevacizumab; Genentech), is available for the treatment of 5 types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent…

In patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), treatment with osimertinib and gefitinib plus pemetrexed-based chemotherapy was found to be superior to other first-line therapies, according to a systematic review and network meta-analysis published in the BMJ. For this investigation, study authors searched various databases from inception through May…

Mvasi (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and Kanjinti (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab) have been made available by Amgen and Allergan.  Mvasi, a vascular endothelial growth factor inhibitor, is indicated to treat: Metastatic colorectal cancer, in combination with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment.  Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan-…

The FDA has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).